Scandion Oncology announces that one of its founders, Saniona, has reduced its shareholding to below 15% of the total share amount
Scandion Oncology A/S (“Scandion Oncology”) announces that Saniona has reduced its ownership stake in Scandion Oncology A/S to below 15%. Saniona, together with CEO Nils Brünner and CSO Jan Stenvang initially founded Scandion Oncology A/S in 2017. After the last capital raise in June 2019, Saniona owned approximately 18% of Scandion Oncology. Proceeds from sales of shares will be used to continue Saniona’s advancement of their pipeline, including mid/late-stage clinical trials with Tesomet.Nils Brünner, CEO of Scandion Oncology says: “We are very grateful for the constructive and valuable